


Correction: Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

Kristensen LE, Danese S, Yndestad A, *et al.* Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. *Ann Rheum Dis* 2023;82:901-910. doi:10.1136/ard-2022-223715

In figure 1C of the originally published version of the manuscript, the plotted value for All cause death for the Age ≥ 65 years and Ever smoked group showed the incidence rate (95% Confidence Interval [CI]) (1.81 (1.15, 2.71)) instead of the hazard ratio (HR) vs tumour necrosis factor inhibitors (TNFi (95% CI)) (2.09 (0.85, 5.13)).

This data point has now been corrected to show the HR vs TNFi (95% CI). The corrected figure panel is included below.



OPEN ACCESS

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Ann Rheum Dis 2024;83:e11. doi:10.1136/ard-2022-223715corr1

